MK-677 (Ibutamoren): Growth Hormone, Appetite and Blood Sugar

MK-677, also called ibutamoren, was developed by Merck in the 1990s as a way to raise growth hormone without injections. It reached several clinical trials, produced real changes in hormone levels, and then stalled. Today it is sold as a research chemical and is often grouped with SARMs. This guide explains what it does, what the human studies showed and where the problems lie.

How MK-677 works

Your stomach releases ghrelin when you are hungry. Besides driving appetite, ghrelin binds a receptor in the pituitary and the hypothalamus that triggers pulses of growth hormone. MK-677 is a small molecule that binds the same receptor and stays active for about 24 hours. Growth hormone pulses become larger, and the liver responds by making more IGF-1, the hormone behind most of growth hormone’s effects on tissue.

Unlike injected growth hormone, MK-677 keeps the body’s own feedback loops intact. IGF-1 still restrains further release, so levels rise into a high-normal range rather than without limit.

What the trials found

Older adults, one year

The largest study, published in 2008 by Ralf Nass and colleagues, gave healthy adults aged 60 to 81 MK-677 or a placebo for a year. IGF-1 rose to levels typical of young adults. Fat-free mass increased by about a kilogram compared with placebo, but strength and physical function did not improve. Fasting glucose rose and insulin sensitivity fell, and some participants developed swelling and muscle aches.

Protein breakdown during dieting

A short 1998 study put healthy young men on a calorie-restricted diet. Those taking MK-677 lost less nitrogen, a marker of muscle protein breakdown. This is where the bodybuilding interest began, although the study lasted only weeks.

Sleep

Small sleep-lab studies found more deep sleep and REM sleep in both young and older men taking MK-677. Many users report vivid dreams, which fits that finding.

Hip fracture recovery

A trial in older patients recovering from hip fractures was stopped early. A small number of patients on MK-677 developed congestive heart failure, likely related to fluid retention in a frail group. The gait benefits the researchers hoped for were modest.

Side effects in the research

Effect	Why it happens	Who should be most careful
Strong hunger	Ghrelin receptor activation	Anyone in a calorie deficit
Higher fasting glucose, lower insulin sensitivity	Growth hormone opposes insulin	People with prediabetes, a family history of diabetes or high HbA1c
Water retention, puffy hands and feet	Growth hormone causes sodium retention	People with high blood pressure or heart disease
Numb or tingling hands	Fluid pressing on the wrist nerve	Desk workers, people with carpal tunnel history
Joint and muscle aches	Fluid and tissue changes	Lifters with existing tendon problems

Long-term questions nobody has answered

Raising IGF-1 for long periods is not risk-free. Large population studies link high-normal IGF-1 with a higher risk of some cancers, while low IGF-1 is linked with other problems, so the relationship is complicated. No long-term safety study of MK-677 exists, and the year-long trial in older adults was too small to settle the question.

MK-677 compared with other growth hormone routes

Practical safety points

• Check fasting glucose, HbA1c and blood pressure before and during use.
• Stop and seek care for shortness of breath, swelling that does not settle or chest discomfort.
• Combining it with other compounds that raise blood sugar or water retention compounds the risk.
• Tested athletes should avoid it entirely: growth hormone secretagogues are banned at all times.

Our listings for MK-677 by Genetix Pharma and Zionova MK-677 carry the label strength and storage details. As with any research compound, a doctor and baseline bloodwork come first.